Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Italy Fines Apple €98.6 Million Over App Store Dominance 
WARREN, N.J., March 28, 2016 -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm drug delivery technology to improve patient outcomes and address unmet needs, today provided an update on the development of PharmFilm Tadalafil for the treatment of erectile dysfunction. The Company has completed a pilot Pharmacokinetic (PK) study and, following a recent meeting with the U.S. Food and Drug Administration (FDA), plans on continuing its development efforts.
Tadalafil is a PDE5 inhibitor currently marketed in pill form for the treatment of erectile dysfunction and benign prostatic hyperplasia (BPH) under the brand name Cialis®, and for treatment of pulmonary arterial hypertension under the brand name Adcirca®. PharmFilm Tadalafil will be offered in single pack doses that can be carried easily without the necessity of a pill bottle. The product is discrete, portable, and can be taken with or without water.
“We are extremely pleased with the progress we have made in the development of PharmFilm Tadalafil,” said Keith Kendall, CEO of MonoSol Rx. “The success of our pilot PK study and positive outcome of our FDA meeting are important milestones in the development program, and we look forward to its further advancement.”
MonoSol Rx is currently exploring partnership opportunities for PharmFilm Tadalafil and has engaged ESC Advisors, a division of KEMA Partners LLC, to manage the partnering process.
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products. MonoSol Rx 's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com. More information about PharmFilm can be found at www.pharmfilm.com.
Contact MonoSol Rx Jessica Patel [email protected] The Ruth Group Lee Roth [email protected] (646) 536-7012
